,,RVXot,,,,,,,correct!,,,,,,,,DM noted back in the fall of 2015 that the trial would have TLD on or before December 2017,,,,,,,,,,,,the first patient was dosed on November 11th, 2015 and the trial was logged as being a 102 week trial.................that would take us into November 2017,,,,,,,,,it was a well distributed piece of info at the time and I based my buy in of additional shares doubling my position based on this knowledge received from our Team. Especially since the trial was told to us to be already funded,,,,dilution thus was not an issue going forward,,,,,along with that,,,also knowing that our KD had offered to support 208 thru to appoval....it was a no brainer as they say,,,,so I believed RVX at the time that we were truely in the drivers seat going forward,,,,,however we found out rather quickly that Managements' expectations were seriously far from reality in the BioTech world,,,,,,,,, it wasnt until early 2016 that the timeline started to change and TLD was expected mid 2018....and as time progressed it changed again and again,,,,,etc,,,,,,,,,,,,